DNA-Loaded Nanoparticles Reprogram the Tumor Immune Microenvironment to Treat Brain Tumors.

Area of Science:

• Oncology
• Nanotechnology
• Immunotherapy

Background:

• Brain tumors, including glioblastoma (GBM) and meningioma, have high recurrence and mortality rates despite current treatments.
• Nonviral biodegradable nanoparticles offer a novel strategy to modify the tumor microenvironment and cellular behavior.
• Reprogramming tumor cells and their immune microenvironment is a promising therapeutic avenue.

Purpose of the Study:

• To investigate the efficacy of poly(beta-amino ester) nanoparticles delivering immunostimulatory genes (4-1BBL and IL-12) for brain tumor treatment.
• To evaluate the potential of these nanoparticles to reprogram brain tumor cells into tumor-associated antigen-presenting cells (tAPCs).
• To assess the impact on tumor growth, regression, and long-term survival in preclinical models.

Main Methods:

• Localized delivery of poly(beta-amino ester) nanoparticles loaded with 4-1BBL and IL-12 DNA.
• Utilizing a humanized mouse model with human meningioma (IOMM-Lee) and an immunocompetent syngeneic model with mouse glioblastoma (CT-2A).
• Assessing tumor growth, immune cell infiltration, and survival rates post-treatment.

Main Results:

• Nanoparticle delivery significantly reduced tumor growth in both meningioma and glioblastoma models.
• Complete tumor regression and long-term survival were observed in a subset of treated animals.
• The 4-1BBL/IL-12 gene delivery platform demonstrated antigen-agnostic capabilities, activating cytotoxic T-cells and improving immune cell infiltration.

Conclusions:

• Nonviral nanoparticle-mediated gene delivery is an effective strategy for reprogramming brain tumors.
• This approach enhances endogenous antitumor immune responses, offering a potential treatment for refractory brain tumors.
• The technology is antigen-agnostic, scalable, and patient-accessible, avoiding viral vectors or ex vivo manufacturing.